A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

NCT03850067 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: CC-90011
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Nivolumab

Sponsor

Celgene